PYC THERAPEUTICS LIMITED - Announcements

6.43%

$1.33

Market Cap $772.8M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

PYC	Approval to Escalate Dosing in Kidney Disease Clinical Trial	PRICE SENSITIVE	08/08/25	299.53KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	21/07/25	589.67KB	Share
PYC	Approval to Progress Kidney Disease Trial to Next Stage	PRICE SENSITIVE	07/07/25	345.58KB	Share
PYC	Fourth Drug Program Progressing to Human Trials	PRICE SENSITIVE	27/06/25	2.72MB	Share
PYC	FDA Alignment on Registrational Trial Design RP11 Program	PRICE SENSITIVE	23/06/25	271.4KB	Share
PYC	SRC Approves Dose Escalation in ADOA Clinical Trial	PRICE SENSITIVE	11/06/25	377.2KB	Share
PYC	Approval to Escalate Dosing in Kidney Disease Trial	PRICE SENSITIVE	26/05/25	507.43KB	Share
PYC	Presentation of Clinical Proof of Concept in Lead Program	PRICE SENSITIVE	28/04/25	854.95KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/25	465.75KB	Share
PYC	Completion of Entitlement Offer	PRICE SENSITIVE	17/04/25	219.2KB	Share
PYC	First Subject Dosed in PKD Clinical Trial	PRICE SENSITIVE	10/04/25	441.03KB	Share
PYC	Placement of Shortfall	PRICE SENSITIVE	09/04/25	216.79KB	Share
PYC	Completion of Retail Entitlement Offer	PRICE SENSITIVE	18/03/25	236.19KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/25	819.41KB	Share
PYC	Retail Entitlement Offer Booklet	PRICE SENSITIVE	24/02/25	1.78MB	Share
PYC	Completion of Institutional Entitlement Offer	PRICE SENSITIVE	19/02/25	253.16KB	Share
PYC	PYC Equity Raising Presentation	PRICE SENSITIVE	17/02/25	874.52KB	Share
PYC	PYC Equity Raising to Raise up to $146 Million	PRICE SENSITIVE	17/02/25	278.79KB	Share
PYC	Trading Halt	PRICE SENSITIVE	17/02/25	257.19KB	Share
PYC	Approval to Commence Human Trials in Kidney Program	PRICE SENSITIVE	10/02/25	324.62KB	Share
PYC	ADOA Safety Review Committee Approves Dose Escalation	PRICE SENSITIVE	31/01/25	257.38KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/01/25	580.07KB	Share
PYC	US FDA Grants Rare Pediatric Disease Designation to VP-001	PRICE SENSITIVE	20/01/25	224.02KB	Share
PYC	PYC Nominates Fourth Clinical Drug Candidate in PMS Program	PRICE SENSITIVE	16/12/24	339.93KB	Share
PYC	PYC to Progress Kidney Drug Candidate Into Human Trials	PRICE SENSITIVE	27/11/24	2.52MB	Share
PYC	Presentation of RP11 Clinical Trial Data at APVRS 2024	PRICE SENSITIVE	22/11/24	1.31MB	Share
PYC	Consolidation/Split - PYC	PRICE SENSITIVE	11/11/24	23.15KB	Share
PYC	RP11 SRC Approves Dose Escalation to Final Patient Cohort	PRICE SENSITIVE	05/11/24	259.08KB	Share
PYC	First ADOA Patient Dosed in Clinical Trial	PRICE SENSITIVE	01/11/24	279.88KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/10/24	580.87KB	Share
PYC	Interim Update on Progress in RP11 Repeat Dose Trials	PRICE SENSITIVE	22/10/24	272.88KB	Share
PYC	Trading Halt	PRICE SENSITIVE	21/10/24	561.45KB	Share
PYC	US FDA Grants Orphan Drug Designation to PYC Drug Candidate	PRICE SENSITIVE	21/10/24	232.46KB	Share
PYC	Notice of Annual General Meeting/Proxy Form	PRICE SENSITIVE	14/10/24	677.61KB	Share
PYC	FDA Grants Rare Pediatric Disease Designation to PYC-001	PRICE SENSITIVE	30/08/24	247.98KB	Share
PYC	Appendix 4E and Audited Financial Statements	PRICE SENSITIVE	29/08/24	1.09MB	Share
PYC	PYC to Start Human Trials in Second Blinding Eye Disease	PRICE SENSITIVE	15/08/24	273.11KB	Share
PYC	Visual Improvement in Multiple RP11 Patients	PRICE SENSITIVE	12/08/24	377.55KB	Share
PYC	RP11 Clinical Trial Update - Amended	PRICE SENSITIVE	05/08/24	863.26KB	Share
PYC	RP11 Clinical Trial Update	PRICE SENSITIVE	05/08/24	666KB	Share
PYC	Extension of RP11 Single Dose Study Into Multiple Dose Study	PRICE SENSITIVE	23/07/24	336.36KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/07/24	534.97KB	Share
PYC	Initial Dosing Completed in Cohort 1 of RP11 MAD Study	PRICE SENSITIVE	17/07/24	382.77KB	Share
PYC	Commencement of RP11 Multiple Dose Trial	PRICE SENSITIVE	10/07/24	397.55KB	Share
PYC	RP11 Drug Candidate Safe and Well Tolerated	PRICE SENSITIVE	01/07/24	240.23KB	Share
PYC	PMS Drug Candidate Effective In Human Brain Cells	PRICE SENSITIVE	07/06/24	297.34KB	Share
PYC	US FDA Grants Orphan Drug Designation to PYC Drug Candidate	PRICE SENSITIVE	24/05/24	221.82KB	Share
PYC	RP11 Clinical Trial Dosing Completed in Cohort 4	PRICE SENSITIVE	16/05/24	480.02KB	Share
PYC	Successful GLP Tox Studies in Second Blinding Eye Disease	PRICE SENSITIVE	14/05/24	378.74KB	Share
PYC	Presentation of RP11 Clinical Trial Data at ARVO Conference	PRICE SENSITIVE	06/05/24	1.4MB	Share
PYC	RP11 Drug Candidate Progressing to Mid-Stage Human Trials	PRICE SENSITIVE	29/04/24	281.37KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/24	375.34KB	Share
PYC	Kidney Disease Drug Candidate Progressing to Human Trials	PRICE SENSITIVE	22/04/24	280.51KB	Share
PYC	$74.6 Million Extension of Cash Runway	PRICE SENSITIVE	10/04/24	248.55KB	Share
PYC	Retail Entitlement Offer Booklet	PRICE SENSITIVE	20/03/24	2.09MB	Share
PYC	Completion of Institutional Entitlement Offer	PRICE SENSITIVE	18/03/24	235.44KB	Share
PYC	PYC Equity Raising Presentation	PRICE SENSITIVE	14/03/24	1.52MB	Share
PYC	PYC Equity Raising to Raise up to $74.6 Million	PRICE SENSITIVE	14/03/24	269.81KB	Share
PYC	Trading Halt	PRICE SENSITIVE	14/03/24	284.75KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/24	796.58KB	Share
PYC	RP11 Clinical Trial - Dosing Completed in Cohort 3	PRICE SENSITIVE	28/02/24	348.64KB	Share
PYC	Receipt of $4.5m Collaboration Fee	PRICE SENSITIVE	16/02/24	144.77KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/24	367.07KB	Share
PYC	AI Driven Drug Discovery Collaboration with Google Cloud	PRICE SENSITIVE	02/01/24	176.79KB	Share
PYC	RP11 Clinical Trial Progressing To High Dose Cohort	PRICE SENSITIVE	18/12/23	257.68KB	Share
PYC	Response to Price Query	PRICE SENSITIVE	30/11/23	305.03KB	Share
PYC	Supplementary Information	PRICE SENSITIVE	16/11/23	519.24KB	Share
PYC	New Drug For Major Kidney Disease Effective In Human Models	PRICE SENSITIVE	13/11/23	510.34KB	Share
PYC	PYC and FDA Align On Clinical Trial Pathway in ADOA	PRICE SENSITIVE	06/11/23	229.61KB	Share
PYC	RP11 Clinical Trial Dosing Completed In Patient Cohort 2	PRICE SENSITIVE	03/11/23	263.51KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/10/23	378.78KB	Share
PYC	PYC-001 Effective In Both NHPs and Patient-Derived Models	PRICE SENSITIVE	04/10/23	463.16KB	Share
PYC	Safety Review Committee Approves Dose Escalation	PRICE SENSITIVE	22/09/23	244.54KB	Share
PYC	Appendix 4E and Audited Financial Statements	PRICE SENSITIVE	31/08/23	2.11MB	Share
PYC	RP11 Clinical Trial Dosing Completed In Patient Cohort 1	PRICE SENSITIVE	17/08/23	222.48KB	Share
PYC	PYC Increases Ownership of VP-001 Program	PRICE SENSITIVE	10/08/23	226.93KB	Share
PYC	PYC Receives FDA Fast Track Designation	PRICE SENSITIVE	02/08/23	228.66KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	372.56KB	Share
PYC	Successful Toxicology Results Pave Way for Phase 2 Trial	PRICE SENSITIVE	18/07/23	263.82KB	Share
PYC	FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL	PRICE SENSITIVE	30/06/23	252.93KB	Share
PYC	Placement Supporting Document	PRICE SENSITIVE	11/05/23	1.34MB	Share
PYC	Successful Completion of $30m Placement	PRICE SENSITIVE	11/05/23	244.21KB	Share
PYC	Trading Halt	PRICE SENSITIVE	09/05/23	596.74KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	403.56KB	Share
PYC	Commencement of First Clinical Study in RP11	PRICE SENSITIVE	26/04/23	249.84KB	Share
PYC	Second Drug Program Progressing to Human Trials	PRICE SENSITIVE	03/04/23	358.21KB	Share
PYC	FDA Clears PYC to Commence First Human Trials in RP11	PRICE SENSITIVE	06/03/23	177.28KB	Share
PYC	Trading Halt	PRICE SENSITIVE	02/03/23	570.58KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.02MB	Share
PYC	VP-001 IND Lodgement	PRICE SENSITIVE	02/02/23	158.05KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/01/23	223.22KB	Share
PYC	PYC Increases Ownership of VP-001 Program	PRICE SENSITIVE	29/11/22	163.64KB	Share
PYC	Successful Toxicology Studies Pave Way for Human Trials	PRICE SENSITIVE	07/11/22	223.45KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	446.75KB	Share
PYC	Central Nervous System Drug Program Added to PYC Pipeline	PRICE SENSITIVE	27/09/22	256.59KB	Share
PYC	Preliminary Final Report	PRICE SENSITIVE	31/08/22	788.67KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/07/22	231.28KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	238.74KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	2.31MB	Share
PYC	PYC Increases Shareholding in Vision Pharma	PRICE SENSITIVE	17/02/22	161.82KB	Share

PYC Approval to Escalate Dosing in Kidney Disease Clinical Trial
08/08/25	PRICE SENSITIVE	299.53KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
21/07/25	PRICE SENSITIVE	589.67KB	Share
PYC Approval to Progress Kidney Disease Trial to Next Stage
07/07/25	PRICE SENSITIVE	345.58KB	Share
PYC Fourth Drug Program Progressing to Human Trials
27/06/25	PRICE SENSITIVE	2.72MB	Share
PYC FDA Alignment on Registrational Trial Design RP11 Program
23/06/25	PRICE SENSITIVE	271.4KB	Share
PYC SRC Approves Dose Escalation in ADOA Clinical Trial
11/06/25	PRICE SENSITIVE	377.2KB	Share
PYC Approval to Escalate Dosing in Kidney Disease Trial
26/05/25	PRICE SENSITIVE	507.43KB	Share
PYC Presentation of Clinical Proof of Concept in Lead Program
28/04/25	PRICE SENSITIVE	854.95KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
24/04/25	PRICE SENSITIVE	465.75KB	Share
PYC Completion of Entitlement Offer
17/04/25	PRICE SENSITIVE	219.2KB	Share
PYC First Subject Dosed in PKD Clinical Trial
10/04/25	PRICE SENSITIVE	441.03KB	Share
PYC Placement of Shortfall
09/04/25	PRICE SENSITIVE	216.79KB	Share
PYC Completion of Retail Entitlement Offer
18/03/25	PRICE SENSITIVE	236.19KB	Share
PYC Half Yearly Report and Accounts
27/02/25	PRICE SENSITIVE	819.41KB	Share
PYC Retail Entitlement Offer Booklet
24/02/25	PRICE SENSITIVE	1.78MB	Share
PYC Completion of Institutional Entitlement Offer
19/02/25	PRICE SENSITIVE	253.16KB	Share
PYC PYC Equity Raising Presentation
17/02/25	PRICE SENSITIVE	874.52KB	Share
PYC PYC Equity Raising to Raise up to $146 Million
17/02/25	PRICE SENSITIVE	278.79KB	Share
PYC Trading Halt
17/02/25	PRICE SENSITIVE	257.19KB	Share
PYC Approval to Commence Human Trials in Kidney Program
10/02/25	PRICE SENSITIVE	324.62KB	Share
PYC ADOA Safety Review Committee Approves Dose Escalation
31/01/25	PRICE SENSITIVE	257.38KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
29/01/25	PRICE SENSITIVE	580.07KB	Share
PYC US FDA Grants Rare Pediatric Disease Designation to VP-001
20/01/25	PRICE SENSITIVE	224.02KB	Share
PYC PYC Nominates Fourth Clinical Drug Candidate in PMS Program
16/12/24	PRICE SENSITIVE	339.93KB	Share
PYC PYC to Progress Kidney Drug Candidate Into Human Trials
27/11/24	PRICE SENSITIVE	2.52MB	Share
PYC Presentation of RP11 Clinical Trial Data at APVRS 2024
22/11/24	PRICE SENSITIVE	1.31MB	Share
PYC Consolidation/Split - PYC
11/11/24	PRICE SENSITIVE	23.15KB	Share
PYC RP11 SRC Approves Dose Escalation to Final Patient Cohort
05/11/24	PRICE SENSITIVE	259.08KB	Share
PYC First ADOA Patient Dosed in Clinical Trial
01/11/24	PRICE SENSITIVE	279.88KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
25/10/24	PRICE SENSITIVE	580.87KB	Share
PYC Interim Update on Progress in RP11 Repeat Dose Trials
22/10/24	PRICE SENSITIVE	272.88KB	Share
PYC Trading Halt
21/10/24	PRICE SENSITIVE	561.45KB	Share
PYC US FDA Grants Orphan Drug Designation to PYC Drug Candidate
21/10/24	PRICE SENSITIVE	232.46KB	Share
PYC Notice of Annual General Meeting/Proxy Form
14/10/24	PRICE SENSITIVE	677.61KB	Share
PYC FDA Grants Rare Pediatric Disease Designation to PYC-001
30/08/24	PRICE SENSITIVE	247.98KB	Share
PYC Appendix 4E and Audited Financial Statements
29/08/24	PRICE SENSITIVE	1.09MB	Share
PYC PYC to Start Human Trials in Second Blinding Eye Disease
15/08/24	PRICE SENSITIVE	273.11KB	Share
PYC Visual Improvement in Multiple RP11 Patients
12/08/24	PRICE SENSITIVE	377.55KB	Share
PYC RP11 Clinical Trial Update - Amended
05/08/24	PRICE SENSITIVE	863.26KB	Share
PYC RP11 Clinical Trial Update
05/08/24	PRICE SENSITIVE	666KB	Share
PYC Extension of RP11 Single Dose Study Into Multiple Dose Study
23/07/24	PRICE SENSITIVE	336.36KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
22/07/24	PRICE SENSITIVE	534.97KB	Share
PYC Initial Dosing Completed in Cohort 1 of RP11 MAD Study
17/07/24	PRICE SENSITIVE	382.77KB	Share
PYC Commencement of RP11 Multiple Dose Trial
10/07/24	PRICE SENSITIVE	397.55KB	Share
PYC RP11 Drug Candidate Safe and Well Tolerated
01/07/24	PRICE SENSITIVE	240.23KB	Share
PYC PMS Drug Candidate Effective In Human Brain Cells
07/06/24	PRICE SENSITIVE	297.34KB	Share
PYC US FDA Grants Orphan Drug Designation to PYC Drug Candidate
24/05/24	PRICE SENSITIVE	221.82KB	Share
PYC RP11 Clinical Trial Dosing Completed in Cohort 4
16/05/24	PRICE SENSITIVE	480.02KB	Share
PYC Successful GLP Tox Studies in Second Blinding Eye Disease
14/05/24	PRICE SENSITIVE	378.74KB	Share
PYC Presentation of RP11 Clinical Trial Data at ARVO Conference
06/05/24	PRICE SENSITIVE	1.4MB	Share
PYC RP11 Drug Candidate Progressing to Mid-Stage Human Trials
29/04/24	PRICE SENSITIVE	281.37KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
26/04/24	PRICE SENSITIVE	375.34KB	Share
PYC Kidney Disease Drug Candidate Progressing to Human Trials
22/04/24	PRICE SENSITIVE	280.51KB	Share
PYC $74.6 Million Extension of Cash Runway
10/04/24	PRICE SENSITIVE	248.55KB	Share
PYC Retail Entitlement Offer Booklet
20/03/24	PRICE SENSITIVE	2.09MB	Share
PYC Completion of Institutional Entitlement Offer
18/03/24	PRICE SENSITIVE	235.44KB	Share
PYC PYC Equity Raising Presentation
14/03/24	PRICE SENSITIVE	1.52MB	Share
PYC PYC Equity Raising to Raise up to $74.6 Million
14/03/24	PRICE SENSITIVE	269.81KB	Share
PYC Trading Halt
14/03/24	PRICE SENSITIVE	284.75KB	Share
PYC Half Yearly Report and Accounts
29/02/24	PRICE SENSITIVE	796.58KB	Share
PYC RP11 Clinical Trial - Dosing Completed in Cohort 3
28/02/24	PRICE SENSITIVE	348.64KB	Share
PYC Receipt of $4.5m Collaboration Fee
16/02/24	PRICE SENSITIVE	144.77KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
25/01/24	PRICE SENSITIVE	367.07KB	Share
PYC AI Driven Drug Discovery Collaboration with Google Cloud
02/01/24	PRICE SENSITIVE	176.79KB	Share
PYC RP11 Clinical Trial Progressing To High Dose Cohort
18/12/23	PRICE SENSITIVE	257.68KB	Share
PYC Response to Price Query
30/11/23	PRICE SENSITIVE	305.03KB	Share
PYC Supplementary Information
16/11/23	PRICE SENSITIVE	519.24KB	Share
PYC New Drug For Major Kidney Disease Effective In Human Models
13/11/23	PRICE SENSITIVE	510.34KB	Share
PYC PYC and FDA Align On Clinical Trial Pathway in ADOA
06/11/23	PRICE SENSITIVE	229.61KB	Share
PYC RP11 Clinical Trial Dosing Completed In Patient Cohort 2
03/11/23	PRICE SENSITIVE	263.51KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
25/10/23	PRICE SENSITIVE	378.78KB	Share
PYC PYC-001 Effective In Both NHPs and Patient-Derived Models
04/10/23	PRICE SENSITIVE	463.16KB	Share
PYC Safety Review Committee Approves Dose Escalation
22/09/23	PRICE SENSITIVE	244.54KB	Share
PYC Appendix 4E and Audited Financial Statements
31/08/23	PRICE SENSITIVE	2.11MB	Share
PYC RP11 Clinical Trial Dosing Completed In Patient Cohort 1
17/08/23	PRICE SENSITIVE	222.48KB	Share
PYC PYC Increases Ownership of VP-001 Program
10/08/23	PRICE SENSITIVE	226.93KB	Share
PYC PYC Receives FDA Fast Track Designation
02/08/23	PRICE SENSITIVE	228.66KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	372.56KB	Share
PYC Successful Toxicology Results Pave Way for Phase 2 Trial
18/07/23	PRICE SENSITIVE	263.82KB	Share
PYC FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL
30/06/23	PRICE SENSITIVE	252.93KB	Share
PYC Placement Supporting Document
11/05/23	PRICE SENSITIVE	1.34MB	Share
PYC Successful Completion of $30m Placement
11/05/23	PRICE SENSITIVE	244.21KB	Share
PYC Trading Halt
09/05/23	PRICE SENSITIVE	596.74KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	403.56KB	Share
PYC Commencement of First Clinical Study in RP11
26/04/23	PRICE SENSITIVE	249.84KB	Share
PYC Second Drug Program Progressing to Human Trials
03/04/23	PRICE SENSITIVE	358.21KB	Share
PYC FDA Clears PYC to Commence First Human Trials in RP11
06/03/23	PRICE SENSITIVE	177.28KB	Share
PYC Trading Halt
02/03/23	PRICE SENSITIVE	570.58KB	Share
PYC Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.02MB	Share
PYC VP-001 IND Lodgement
02/02/23	PRICE SENSITIVE	158.05KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
20/01/23	PRICE SENSITIVE	223.22KB	Share
PYC PYC Increases Ownership of VP-001 Program
29/11/22	PRICE SENSITIVE	163.64KB	Share
PYC Successful Toxicology Studies Pave Way for Human Trials
07/11/22	PRICE SENSITIVE	223.45KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	446.75KB	Share
PYC Central Nervous System Drug Program Added to PYC Pipeline
27/09/22	PRICE SENSITIVE	256.59KB	Share
PYC Preliminary Final Report
31/08/22	PRICE SENSITIVE	788.67KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
27/07/22	PRICE SENSITIVE	231.28KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	238.74KB	Share
PYC Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	2.31MB	Share
PYC PYC Increases Shareholding in Vision Pharma
17/02/22	PRICE SENSITIVE	161.82KB	Share

REFRESH

1 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.33		Change 0.080(6.43%)		Mkt cap ! $772.8M

Open	High	Low	Value	Volume
$1.27	$1.35	$1.21	$763.8K	595.4K

Buyers (Bids)

No.	Vol.	Price($)
2	97719	$1.30

Sellers (Offers)

Price($)	Vol.	No.
$1.33	6599	1

View Market Depth

No.	Vol.	Price($)
2	97719	1.300
1	4027	1.240
1	40000	1.220
1	1000	1.200
2	10830	1.190

Price($)	Vol.	No.
1.325	6599	1
1.395	7168	1
1.400	18450	1
1.420	26097	2
1.430	13000	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories